Ali Jafarizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali Jafarizadeh has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Siamak Pedrammehr
Faculty of Design, Tabriz Islamic Art University, Tabriz 5164736931, Iran
12 shared publications - Navid Sobhi
Translational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
11 shared publications - Roohallah Alizadehsani
Institute for Intelligent Systems Research and Innovation (IISRI), Deakin University, Waurn Ponds, VIC, Australia
10 shared publications - Hadi Vahedi
Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran
9 shared publications - Mirsaeed Abdollahi
Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran
9 shared publications - Hamidreza Ashayeri
Research Center for Evidence-Based Medicine, Iranian EBM Centre: A JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
7 shared publications
Latest Publications
- Open Access
Uveal and cutaneous melanoma share a common mutation with distinct prognostic implications: A bioinformatic study
What was known before: Uveal melanoma (UM) and cutaneous melanoma (CM) arise from a common melanocytic lineage but exhibit distinct genetic landscapes, biological behavior, and clinical outcomes. Pigmentation-related genes, including IRF4 and HERC2, have been implicated in melanoma susceptibility and prognosis; however, the extent of shared genetic variants between UM and CM has remained unclear. Previous studies have primarily investigated UM and CM separately, leaving limited understanding of their common genetic architecture and potential shared prognostic biomarkers. What this study adds: This bioinformatic analysis identified only two shared validated genetic variants between UM and CM across publicly available databases: rs12203592 (IRF4) and rs12913832 (HERC2). Protein–protein interaction analysis demonstrated that IRF4 and OCA2 directly interact with HERC2, supporting a biologically plausible pigmentation-related pathway linking the two melanoma subtypes. The findings suggest that IRF4 may represent a common prognostic biomarker across both UM and CM, while combined assessment of IRF4 and HERC2 could improve future risk stratification and facilitate more personalized therapeutic approaches. Background: Uveal melanoma (UM) and cutaneous melanoma (CM) both originate from the same cell line. This proposes the possibility of a shared mechanism between entities, requiring explicit investigation. Methods: Data from GWAS Catalog and DisGeNET were used to identify shared variation-disease associations (VDAs) between UM and CM. The results were validated using the Ensembl database. In the next step, the STRING database was used to identify the protein– protein interaction. Results: Subsequently, 109 unique VDAs were identified for UM and 880 for CM. However, only 2 VDAs were found to be shared among UM and CM in different ethnic groups. These shared VDAs were rs12203592 of the IRF4 gene, rs12913832 of the HECT and RLD domain-containing E3 ubiquitin protein ligase 2 (HERC2) gene. Notably, PPI network assessment through STRING showcased that OCA2 and IRF4 directly interacted with HERC2. Conclusion: While HERC2 acts as a poor prognostic factor in uveal melanoma, IRF4 status is a key prognostic indicator in both UM and CM. Identifying IRF4 allele contributions enables a better understanding of melanoma pathogenesis and fosters the development of disease-specific approaches.
Open AccessUveal and cutaneous melanoma share a common mutation with distinct prognostic implications: A bioinformatic study
What was known before: Uveal melanoma (UM) and cutaneous melanoma (CM) arise from a common melanocytic lineage but exhibit distinct genetic landscapes, biological behavior, and clinical outcomes. Pigmentation-related genes, including IRF4 and HERC2, have been implicated in melanoma susceptibility and prognosis; however, the extent of shared genetic variants between UM and CM has remained unclear. Previous studies have primarily investigated UM and CM separately, leaving limited understanding of their common genetic architecture and potential shared prognostic biomarkers. What this study adds: This bioinformatic analysis identified only two shared validated genetic variants between UM and CM across publicly available databases: rs12203592 (IRF4) and rs12913832 (HERC2). Protein–protein interaction analysis demonstrated that IRF4 and OCA2 directly interact with HERC2, supporting a biologically plausible pigmentation-related pathway linking the two melanoma subtypes. The findings suggest that IRF4 may represent a common prognostic biomarker across both UM and CM, while combined assessment of IRF4 and HERC2 could improve future risk stratification and facilitate more personalized therapeutic approaches. Background: Uveal melanoma (UM) and cutaneous melanoma (CM) both originate from the same cell line. This proposes the possibility of a shared mechanism between entities, requiring explicit investigation. Methods: Data from GWAS Catalog and DisGeNET were used to identify shared variation-disease associations (VDAs) between UM and CM. The results were validated using the Ensembl database. In the next step, the STRING database was used to identify the protein– protein interaction. Results: Subsequently, 109 unique VDAs were identified for UM and 880 for CM. However, only 2 VDAs were found to be shared among UM and CM in different ethnic groups. These shared VDAs were rs12203592 of the IRF4 gene, rs12913832 of the HECT and RLD domain-containing E3 ubiquitin protein ligase 2 (HERC2) gene. Notably, PPI network assessment through STRING showcased that OCA2 and IRF4 directly interacted with HERC2. Conclusion: While HERC2 acts as a poor prognostic factor in uveal melanoma, IRF4 status is a key prognostic indicator in both UM and CM. Identifying IRF4 allele contributions enables a better understanding of melanoma pathogenesis and fosters the development of disease-specific approaches.
- Open Access
- 10 August 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1) , 479
Ocular findings in pediatric candidates for cochlear implantation with bilateral sensorineural hearing loss: a brief report from northwestern Iran
Background: The presence of ocular abnormalities in patients with sensorineural hearing loss (SNHL) may affect children’s developmental milestones due to impairment of primary sensory inputs. This study aimed to evaluate the prevalence of different ophthalmologic abnormalities in pediatric patients with bilateral SNHL who were candidates for cochlear implantation (CI). Methods: We performed a retrospective medical chart review of 261 pediatric patients under 13 years of age with bilateral SNHL who were candidates for CI and were evaluated at a tertiary cochlear implantation referral center in northwestern Iran between March 21, 2017, and June 20, 2025. Ophthalmologic findings were assessed as the main outcome measures. Results: The overall prevalence of ocular findings was 19.5%. Cardiac abnormalities were observed in 17.6% of patients, and refractive errors were identified in 8.4%. Jaundice was the most common prenatal complication, and 36.8% of patients had a history of neurologic complications. Ocular, cardiologic, and neurologic manifestations occurred independently of one another, with no significant pairwise co-occurrence among the three systems. Conclusions: Our findings highlight the need for a multidisciplinary approach in candidates for CI with bilateral SNHL. Comprehensive ophthalmologic evaluation is essential in this population, with particular attention to refractive errors, ocular alignment, and fundus assessment. Because ocular, cardiologic, and neurologic findings occurred independently in the exploratory analysis, screening for each system should be pursued comprehensively and in parallel rather than selectively guided by findings in another system. Trial registration: Not applicable.
- 10 August 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1) , 479
Open AccessOcular findings in pediatric candidates for cochlear implantation with bilateral sensorineural hearing loss: a brief report from northwestern Iran
Background: The presence of ocular abnormalities in patients with sensorineural hearing loss (SNHL) may affect children’s developmental milestones due to impairment of primary sensory inputs. This study aimed to evaluate the prevalence of different ophthalmologic abnormalities in pediatric patients with bilateral SNHL who were candidates for cochlear implantation (CI). Methods: We performed a retrospective medical chart review of 261 pediatric patients under 13 years of age with bilateral SNHL who were candidates for CI and were evaluated at a tertiary cochlear implantation referral center in northwestern Iran between March 21, 2017, and June 20, 2025. Ophthalmologic findings were assessed as the main outcome measures. Results: The overall prevalence of ocular findings was 19.5%. Cardiac abnormalities were observed in 17.6% of patients, and refractive errors were identified in 8.4%. Jaundice was the most common prenatal complication, and 36.8% of patients had a history of neurologic complications. Ocular, cardiologic, and neurologic manifestations occurred independently of one another, with no significant pairwise co-occurrence among the three systems. Conclusions: Our findings highlight the need for a multidisciplinary approach in candidates for CI with bilateral SNHL. Comprehensive ophthalmologic evaluation is essential in this population, with particular attention to refractive errors, ocular alignment, and fundus assessment. Because ocular, cardiologic, and neurologic findings occurred independently in the exploratory analysis, screening for each system should be pursued comprehensively and in parallel rather than selectively guided by findings in another system. Trial registration: Not applicable.
- Open Access
Timing of Radiotherapy in Uveal Melanoma: A SEER-Based Comparison of Preoperative, Postoperative, and Intraoperative Approaches
Purpose: To analyze the effect of radiotherapy timing relative to surgery on patients’ survival and mortality rates in uveal melanoma (UM). Design: Retrospective cohort study using registry data from the Surveillance, Epidemiology, and End Results (SEER) database. Subjects: A total of 1,198 patients with UM were extracted from the SEER database and divided into three groups: preoperative radiotherapy, intraoperative radiotherapy (IORT), and postoperative radiotherapy. Methods: UM cases were extracted from the SEER database. Survival curves were generated based on the Kaplan-Meier method. An extended Cox regression was used to estimate the cancer-specific and all-cause mortality. Main Outcome Measures: Overall survival (including median survival) and hazard reductions for cancer-specific and all-cause mortality. Results: Preoperative radiotherapy revealed the highest median survival (4.93 years), followed by postoperative radiotherapy (4.76 years), and IORT (4.02 years). The preoperative strategy reduced the hazard of all-cause mortality by 42%, 50%, and 60% at 5-, 7-, and 10-year follow-up, respectively, compared with IORT. Findings were consistent in the cancer-specific sensitivity analysis (45%, 53%, and 62% reductions at the same time points). However, postoperative radiotherapy did not significantly reduce the cancer-specific mortality in comparison to IORT. Conclusions: Preoperative radiotherapy was associated with higher median overall survival and lower all-cause and cancer-specific mortality than IORT over 10 years of follow-up. Postoperative radiotherapy showed intermediate outcomes that did not differ significantly from IORT. Prospective studies with more detailed data on the temporal relation of radiotherapy timing and surgery are needed to confirm these findings.
Open AccessTiming of Radiotherapy in Uveal Melanoma: A SEER-Based Comparison of Preoperative, Postoperative, and Intraoperative Approaches
Purpose: To analyze the effect of radiotherapy timing relative to surgery on patients’ survival and mortality rates in uveal melanoma (UM). Design: Retrospective cohort study using registry data from the Surveillance, Epidemiology, and End Results (SEER) database. Subjects: A total of 1,198 patients with UM were extracted from the SEER database and divided into three groups: preoperative radiotherapy, intraoperative radiotherapy (IORT), and postoperative radiotherapy. Methods: UM cases were extracted from the SEER database. Survival curves were generated based on the Kaplan-Meier method. An extended Cox regression was used to estimate the cancer-specific and all-cause mortality. Main Outcome Measures: Overall survival (including median survival) and hazard reductions for cancer-specific and all-cause mortality. Results: Preoperative radiotherapy revealed the highest median survival (4.93 years), followed by postoperative radiotherapy (4.76 years), and IORT (4.02 years). The preoperative strategy reduced the hazard of all-cause mortality by 42%, 50%, and 60% at 5-, 7-, and 10-year follow-up, respectively, compared with IORT. Findings were consistent in the cancer-specific sensitivity analysis (45%, 53%, and 62% reductions at the same time points). However, postoperative radiotherapy did not significantly reduce the cancer-specific mortality in comparison to IORT. Conclusions: Preoperative radiotherapy was associated with higher median overall survival and lower all-cause and cancer-specific mortality than IORT over 10 years of follow-up. Postoperative radiotherapy showed intermediate outcomes that did not differ significantly from IORT. Prospective studies with more detailed data on the temporal relation of radiotherapy timing and surgery are needed to confirm these findings.
- Open Access
A Deep Hypergraph Learning Model for Predicting Antimicrobial Combination Effects Across Bacterial Targets
Antimicrobial resistance (AMR) creates an urgent need for efficient strategies to identify effective antibacterial combinations. Combination therapy, including antimicrobial peptides (AMPs) paired with conventional antibiotics, is a promising approach, but exhaustive experimental screening across drug pairs and bacterial targets is impractical. This study introduces a hybrid GCN-based hypergraph neural network (HGNN) for predicting antimicrobial-agent combination outcomes against bacterial targets. Each antimicrobial-agent-antimicrobial-agent-bacterium triplet is represented as a ternary hyperedge, enabling the model to learn context-dependent interaction patterns. The framework integrates SMILES-derived molecular graph embeddings for antimicrobial agents, including conventional antibiotics and AMPs, with taxonomy-derived bacterial representations. The prediction task was formulated as a three-class classification problem: synergy, antagonism, and non-interaction. The non-interaction class included experimentally verified indifferent records and synthetic presumed non-interaction triplets generated by negative sampling. Model development used drug-pair-grouped splitting, five-fold grouped cross-validation within the training/validation partition, and final evaluation on a held-out test set. On the held-out three-class test set, the selected GCN-based HGNN achieved an accuracy of 0.83, weighted F1-score of 0.84, macro F1-score of 0.80, and ROC-AUC of 0.95. Per-class evaluation showed accuracies of 0.80 for synergy, 0.92 for antagonism, and 0.85 for non-interaction. Pair-type analysis showed strong performance across AMP-AMP, AMP-conventional antibiotic, and conventional antibiotic-conventional antibiotic combinations. These findings suggest that hypergraph-based representation learning can support computational prioritization of antimicrobial combinations for experimental follow-up. Further studies will be needed to improve model interpretability and to perform prospective validation of predicted synergistic combinations.
Open AccessA Deep Hypergraph Learning Model for Predicting Antimicrobial Combination Effects Across Bacterial Targets
Antimicrobial resistance (AMR) creates an urgent need for efficient strategies to identify effective antibacterial combinations. Combination therapy, including antimicrobial peptides (AMPs) paired with conventional antibiotics, is a promising approach, but exhaustive experimental screening across drug pairs and bacterial targets is impractical. This study introduces a hybrid GCN-based hypergraph neural network (HGNN) for predicting antimicrobial-agent combination outcomes against bacterial targets. Each antimicrobial-agent-antimicrobial-agent-bacterium triplet is represented as a ternary hyperedge, enabling the model to learn context-dependent interaction patterns. The framework integrates SMILES-derived molecular graph embeddings for antimicrobial agents, including conventional antibiotics and AMPs, with taxonomy-derived bacterial representations. The prediction task was formulated as a three-class classification problem: synergy, antagonism, and non-interaction. The non-interaction class included experimentally verified indifferent records and synthetic presumed non-interaction triplets generated by negative sampling. Model development used drug-pair-grouped splitting, five-fold grouped cross-validation within the training/validation partition, and final evaluation on a held-out test set. On the held-out three-class test set, the selected GCN-based HGNN achieved an accuracy of 0.83, weighted F1-score of 0.84, macro F1-score of 0.80, and ROC-AUC of 0.95. Per-class evaluation showed accuracies of 0.80 for synergy, 0.92 for antagonism, and 0.85 for non-interaction. Pair-type analysis showed strong performance across AMP-AMP, AMP-conventional antibiotic, and conventional antibiotic-conventional antibiotic combinations. These findings suggest that hypergraph-based representation learning can support computational prioritization of antimicrobial combinations for experimental follow-up. Further studies will be needed to improve model interpretability and to perform prospective validation of predicted synergistic combinations.
- Open Access
- 16 April 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Is Current Evidence Sufficient to Establish the Efficacy of Botulinum Toxin A in Treating Persistent Dry Eye Disease? A Systematic Review and Meta‐Analysis of Interventional Studies With a Critical Review Using GRADE Tool
Background and Aims: Standard management of dry eye disease (DED) relies on artificial tears, anti‐inflammatory therapy, and punctal occlusion in selected cases. However, some patients continue to report persistent symptoms. The present article reviewed the efficacy of Botulinum Toxin A (BTX‐A) for DED that remained symptomatic after these interventions, excluding patients with blepharospasm or hemifacial spasm. Methods: We conducted a comprehensive search of seven databases (PubMed, Embase, Web of Science, Scopus, CENTRAL, Science Direct, and ProQuest), supplemented by grey literature searches (ProQuest, Scopus, OATD), hand‐searching key ophthalmology journals, and investigating clinical trial registries (ClinicalTrials. gov, ICTRP, ISRCTN). Inclusion criteria were clinical trials and cohort studies assessing BTX‐A in primary DED. Outcomes included tear break‐up time (TBUT), Schirmer's test, and Ocular Surface Disease Index (OSDI). Meta‐analyses utilized STATA 17, combining standardized mean differences (SMD) for TBUT and Schirmer's test, and mean difference (MD) for OSDI. Evidence certainty was evaluated using GRADE. Results: Out of 5,064 records, five studies (144 eyes) were included. Meta‐analysis indicated no significant improvements in TBUT (Hedges's g = 0.43, 95% CI: −1.34 to 2.20) or Schirmer's test (Hedges's g = 0.23, 95% CI: −0.78 to 1.24). However, OSDI scores showed a significant reduction (MD –14.23; 95% CI: −15.86 to −12.59, p < 0.001), with moderate‐certainty evidence. Conclusions: BTX‐A injections appear to offer symptom relief in persistent DED, though effects on objective measures remain inconclusive, limited by heterogeneity and low power. While initial safety data is favorable, the small number of methodologically weak studies highlights the need for larger, high‐quality trials to clarify BTX‐A's clinical role. PROSPERO Registration: CRD420251031877.
- 16 April 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Open AccessIs Current Evidence Sufficient to Establish the Efficacy of Botulinum Toxin A in Treating Persistent Dry Eye Disease? A Systematic Review and Meta‐Analysis of Interventional Studies With a Critical Review Using GRADE Tool
Background and Aims: Standard management of dry eye disease (DED) relies on artificial tears, anti‐inflammatory therapy, and punctal occlusion in selected cases. However, some patients continue to report persistent symptoms. The present article reviewed the efficacy of Botulinum Toxin A (BTX‐A) for DED that remained symptomatic after these interventions, excluding patients with blepharospasm or hemifacial spasm. Methods: We conducted a comprehensive search of seven databases (PubMed, Embase, Web of Science, Scopus, CENTRAL, Science Direct, and ProQuest), supplemented by grey literature searches (ProQuest, Scopus, OATD), hand‐searching key ophthalmology journals, and investigating clinical trial registries (ClinicalTrials. gov, ICTRP, ISRCTN). Inclusion criteria were clinical trials and cohort studies assessing BTX‐A in primary DED. Outcomes included tear break‐up time (TBUT), Schirmer's test, and Ocular Surface Disease Index (OSDI). Meta‐analyses utilized STATA 17, combining standardized mean differences (SMD) for TBUT and Schirmer's test, and mean difference (MD) for OSDI. Evidence certainty was evaluated using GRADE. Results: Out of 5,064 records, five studies (144 eyes) were included. Meta‐analysis indicated no significant improvements in TBUT (Hedges's g = 0.43, 95% CI: −1.34 to 2.20) or Schirmer's test (Hedges's g = 0.23, 95% CI: −0.78 to 1.24). However, OSDI scores showed a significant reduction (MD –14.23; 95% CI: −15.86 to −12.59, p < 0.001), with moderate‐certainty evidence. Conclusions: BTX‐A injections appear to offer symptom relief in persistent DED, though effects on objective measures remain inconclusive, limited by heterogeneity and low power. While initial safety data is favorable, the small number of methodologically weak studies highlights the need for larger, high‐quality trials to clarify BTX‐A's clinical role. PROSPERO Registration: CRD420251031877.
- 7 April 2026
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 109 (7) , 1-3
Re: ‘The effect of botulinum toxin A on dry eye disease and syndromes’
- 7 April 2026
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 109 (7) , 1-3
Re: ‘The effect of botulinum toxin A on dry eye disease and syndromes’
- 4 January 2026
- Published by Springer Nature in Eye
- Vol. 40 (3) , 435-436
Botulinum toxin a for dry eye disease: impact of population mixing and statistical issues
- 4 January 2026
- Published by Springer Nature in Eye
- Vol. 40 (3) , 435-436
Botulinum toxin a for dry eye disease: impact of population mixing and statistical issues
- Open Access
- 28 November 2025
- Published by SAGE Publications in Breast Cancer: Basic and Clinical Research
- Vol. 19
Memantine, an NMDA Receptor Antagonist, Attenuates Doxorubicin-Induced Cardiac Oxidative Stress and Inflammation in Mouse 4T1 Breast Cancer Model
Background: Breast cancer is the most common cancer among women, and chemotherapy is a key treatment option. Doxorubicin is frequently used for breast cancer but poses a risk of cardiotoxicity. Recently, memantine, an N-Methyl-D-aspartate antagonist, has shown both antitumor and cardioprotective effects. Objectives: We conducted a study to examine the combined effects of doxorubicin and memantine on the 4T1 cell line in a breast cancer animal model and to assess memantine’s potential in reducing doxorubicin-induced cardiotoxicity in breast cancer model mouse. Design: The 4T1 cell line was cultured and subsequently inoculated into mice. After that animals were randomly divided into four groups: (1) control, (2) memantine, (3) doxorubicin, and (4) memantine + doxorubicin. Methods: After 30 days, mice were sacrificed, and their lungs, liver, and heart were collected for histological analysis. Myeloperoxidase, Malondialdehyde, and TNF-α levels in cardiac tissues were measured, and the TUNEL test was conducted for breast tumors. Results: Our results showed that memantine + doxorubicin reduced MDA activity and TNF-α levels in cardiac tissue in comparison to the doxorubicin group. TUNEL test revealed that the memantine + doxorubicin group demonstrated significantly more tumor cell apoptosis than the mice in other groups ( P -value < 0.05), although tumor volume reduction was not significantly greater than that in the doxorubicin group. Conclusion: This study is the first to demonstrate that memantine can enhance the therapeutic efficacy of doxorubicin chemotherapy while also reducing doxorubicin-induced cardiac oxidative stress and inflammation in a breast cancer model.
- 28 November 2025
- Published by SAGE Publications in Breast Cancer: Basic and Clinical Research
- Vol. 19
Open AccessMemantine, an NMDA Receptor Antagonist, Attenuates Doxorubicin-Induced Cardiac Oxidative Stress and Inflammation in Mouse 4T1 Breast Cancer Model
Background: Breast cancer is the most common cancer among women, and chemotherapy is a key treatment option. Doxorubicin is frequently used for breast cancer but poses a risk of cardiotoxicity. Recently, memantine, an N-Methyl-D-aspartate antagonist, has shown both antitumor and cardioprotective effects. Objectives: We conducted a study to examine the combined effects of doxorubicin and memantine on the 4T1 cell line in a breast cancer animal model and to assess memantine’s potential in reducing doxorubicin-induced cardiotoxicity in breast cancer model mouse. Design: The 4T1 cell line was cultured and subsequently inoculated into mice. After that animals were randomly divided into four groups: (1) control, (2) memantine, (3) doxorubicin, and (4) memantine + doxorubicin. Methods: After 30 days, mice were sacrificed, and their lungs, liver, and heart were collected for histological analysis. Myeloperoxidase, Malondialdehyde, and TNF-α levels in cardiac tissues were measured, and the TUNEL test was conducted for breast tumors. Results: Our results showed that memantine + doxorubicin reduced MDA activity and TNF-α levels in cardiac tissue in comparison to the doxorubicin group. TUNEL test revealed that the memantine + doxorubicin group demonstrated significantly more tumor cell apoptosis than the mice in other groups ( P -value < 0.05), although tumor volume reduction was not significantly greater than that in the doxorubicin group. Conclusion: This study is the first to demonstrate that memantine can enhance the therapeutic efficacy of doxorubicin chemotherapy while also reducing doxorubicin-induced cardiac oxidative stress and inflammation in a breast cancer model.
- Open Access
- 24 November 2025
- Published by Springer Nature in Discover Artificial Intelligence
- Vol. 5 (1) , 351
Application of fuzzy logic and systems in COVID-19 pandemics: a comprehensive review
Purpose: The COVID-19 pandemic has created many new challenges characterized by significant uncertainty. Fuzzy logic systems have been employed to address these uncertainties, contributing to areas such as disease detection, pandemic prediction, behavioral evaluation, healthcare management, and medical devices. Methods: A comprehensive literature review was conducted on studies published between December 2019 and April 2025. Articles were selected from databases including PubMed and Scopus, based on predefined inclusion criteria. Only English-language peer-reviewed articles were included, while review articles, conference abstracts, animal studies, and non-peer-reviewed manuscripts were excluded. Results: A total of 102 studies were included, categorized into five domains: disease detection (17 studies), management strategies (30 studies), pandemic prediction (21 studies), behavioral evaluation (21 studies), and medical devices (13 studies). Fuzzy logic systems demonstrated high diagnostic accuracy, with 11 (65%) of studies in disease detection reporting accuracy rates above 95%. In pandemic prediction, accuracy rates ranged from 80% to 98.60%, while behavioral and management studies largely provided qualitative insights. Medical devices employing fuzzy logic also showed innovations. Conclusion: Fuzzy logic has been widely used to address challenges posed by COVID-19. It has proven highly effective in disease detection and useful in pandemic prediction, behavioral analysis, and resource management by offering valuable insights under uncertain conditions. Notably, the diagnostic domain stands out with fewer qualitative outcomes and higher accuracy rates compared to other applications, highlighting fuzzy logic’s strong suitability for diagnostic purposes. Despite these promising results, further advancements in algorithm development and integration are necessary to unlock its full potential.
- 24 November 2025
- Published by Springer Nature in Discover Artificial Intelligence
- Vol. 5 (1) , 351
Open AccessApplication of fuzzy logic and systems in COVID-19 pandemics: a comprehensive review
Purpose: The COVID-19 pandemic has created many new challenges characterized by significant uncertainty. Fuzzy logic systems have been employed to address these uncertainties, contributing to areas such as disease detection, pandemic prediction, behavioral evaluation, healthcare management, and medical devices. Methods: A comprehensive literature review was conducted on studies published between December 2019 and April 2025. Articles were selected from databases including PubMed and Scopus, based on predefined inclusion criteria. Only English-language peer-reviewed articles were included, while review articles, conference abstracts, animal studies, and non-peer-reviewed manuscripts were excluded. Results: A total of 102 studies were included, categorized into five domains: disease detection (17 studies), management strategies (30 studies), pandemic prediction (21 studies), behavioral evaluation (21 studies), and medical devices (13 studies). Fuzzy logic systems demonstrated high diagnostic accuracy, with 11 (65%) of studies in disease detection reporting accuracy rates above 95%. In pandemic prediction, accuracy rates ranged from 80% to 98.60%, while behavioral and management studies largely provided qualitative insights. Medical devices employing fuzzy logic also showed innovations. Conclusion: Fuzzy logic has been widely used to address challenges posed by COVID-19. It has proven highly effective in disease detection and useful in pandemic prediction, behavioral analysis, and resource management by offering valuable insights under uncertain conditions. Notably, the diagnostic domain stands out with fewer qualitative outcomes and higher accuracy rates compared to other applications, highlighting fuzzy logic’s strong suitability for diagnostic purposes. Despite these promising results, further advancements in algorithm development and integration are necessary to unlock its full potential.